Archon Biosciences
Archon Biosciences develops geometrically tunable protein therapeutics called Antibody Cages (AbCs), which integrate antibody affinity and specificity with generative protein design to target pathways inaccessible to other technologies. Its platform uses AI-driven structural engineering to create biologics with precise control over distribution, engagement, and function for improved treatment of disease. The organization aims to solve challenging drug discovery problems by advancing new classes of biologic medicines.
Facts
- HQ
- Seattle, Washington, US
- Sectors
- Biotechnology Research
- Founded
- 2023 Seattle business license
- Type
- Corporation Seattle business license
- Employees
- 26
- Registered name
- Archon Biosciences Inc Seattle business license
- Stage
- Seed
Is this your organization? Claim it
Protein Design & AI ft. Madrona Venture Group Partner Chris Picardo
How much can we truly engineer at the molecular level? For years, designing functional proteins from scratch felt like an impossible feat, yet breakthroughs in the early 2000s shifted this paradigm. #ProteinDesign #AIinScience #AlphaFold #BioTech #DeepLearning
James Lazarovits - Co-Founder and CEO at Archon Biosciences
James Lazarovits is the CEO and Co-Founder of Archon Biosciences, a leader at the intersection of materials engineering and artificial intelligence. James brings over 15 years of experience building, mentoring, and investing in deep tech startups across AI, software, hardware, and robotics. Before founding Archon, James was at the forefront of AI-driven computational protein design as a post-doctoral fellow and later research faculty at the Institute for Protein Design at the University of Washington, under the direction of 2024 Nobel Laureate, David Baker. There, he contributed to pioneering methods that integrate machine learning and molecular engineering to create next-gen therapeutic…
Archon's Jamie Lazarovits on Unlocking the Full Power of Antibodies With AI
What does it take to move from cutting-edge academic research to launching a biotech company that could transform medicine? In this week's episode of Founded & Funded, Madrona Partner Chris Picardo sat down with Jamie Lazarovitz, CEO and co-founder of Archon Biosciences, to uncover the story behind their groundbreaking protein-based biologics and their unique Antibody Cages (AbCs). From bootstrapping deep tech investments as a student to navigating the challenges of commercializing revolutionary science, Jamie shares the pivotal moments, tough decisions, and key lessons that led to Archon's creation. This isn't just a story for biotech enthusiasts — every founder can…
See all 9 videos about Archon Biosciences.
Seattle Flow is free for everyone.
- Claim and edit your profile
- Get alerts about you, your company, and anything else you care about
- Access the most comprehensive investor list in Seattle
- Join the conversation on news, podcasts, and events
People
-
George Ueda Chief Technology Officer, Co-Founder
-
James Lazarovits Chief Executive Officer, Co-Founder